Induced pluripotent stem cells from a spinal muscular atrophy patient
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy is one of the most common inherited forms of neurological disease leading to infant mortality. Patients have selective loss of lower motor neurons resulting in muscle weakness, paralysis and often death. Although patient fibroblasts have been used extensively to study spinal muscular atrophy, motor neurons have a unique anatomy and physiology which may underlie their vulnerability to the disease process. Here we report the generation of induced pluripotent stem cells from skin fibroblast samples taken from a child with spinal muscular atrophy. These cells expanded robustly in culture, maintained the disease genotype and generated motor neurons that showed selective deficits compared to those derived from the child's unaffected mother. This is the first study to show that human induced pluripotent stem cells can be used to model the specific pathology seen in a genetically inherited disease. As such, it represents a promising resource to study disease mechanisms, screen new drug compounds and develop new therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SMA iPSC-derived motor neurons showed a higher vulnerability with reduced dendritic and axonal length.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Technologies to reprogram adult cells back to a pluripotent state, termed induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006; Yu et al., 2007), provide an unprecedented platform for studying human genetic disorders (Ebert et al., 2009; Mattis et al., 2015).”
From Modeling Psychomotor Retardation using iPSCs from MCT8-Deficient Patients Indicates a Prominent Role for the Blood-Brain Barrier (2017) · cites this paper as Ebert et al., 2009
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“RNA analysis from SMA iPSC-derived motor neuron demonstrates hyperactivation of the endoplasmic reticulum (ER) stress pathway due to activated unfolded SMN [49].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Exploration, normalization, and summaries of high density oligonucleotide array probe level data
Irizarry, R. A. (2003) · Biostatistics · doi:10.1093/biostatistics/4.2.249 · Cited by 10,603
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Self-citationBolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,266
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,151
Pvclust: an R package for assessing the uncertainty in hierarchical clustering
Suzuki, R., & Shimodaira, H. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl117 · Cited by 2,451
Reprogramming of human somatic cells to pluripotency with defined factors
Park, I.-H., Zhao, R., West, J. A., Yabuuchi, A., Huo, H., Ince, T. A., Lerou, P. H., Lensch, M. W., & Daley, G. Q. (2008) · Nature · doi:10.1038/nature06534 · Cited by 2,436
Disease-Specific Induced Pluripotent Stem Cells.
Park, I.-H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., Lensch, M. W., Cowan, C., Hochedlinger, K., & Daley, G. Q. (2008) · Cell · doi:10.1016/j.cell.2008.07.041 · Cited by 2,196
Neuronal specification in the spinal cord: inductive signals and transcriptional codes
Jessell, T. M. (2000) · Nature Reviews Genetics · doi:10.1038/35049541 · Cited by 2,089
Cited by
Items 201–300 of 1,000
Human-induced pluripotent stem cells: potential for neurodegenerative diseases
Ross, C. A., & Akimov, S. S. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu204 · Cited by 110
“Perhaps the first neurologic disease with a characterized iPSC model is spinomuscular atrophy (SMA) (91).”
BackgroundInfluentialEmerging use of stem cells in regenerative medicine
Teo, A. K. K., & Vallier, L. (2010) · Biochemical Journal · doi:10.1042/bj20100102 · Cited by 108
Liras, A. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-131 · Cited by 131
“Good results have also been reported in spinal muscular atrophy [57] and in screening tests in toxicology and pharmacology, for toxic substances for the embryo or for teratogenic substances [58].”
BackgroundModeling human neurological disorders with induced pluripotent stem cells
Imaizumi, Y., & Okano, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12625 · Cited by 109
Rohart, F., Eslami, A., Matigian, N., Bougeard, S., & Lê Cao, K.-A. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1553-8 · Cited by 108
Wada, T., Honda, M., Minami, I., Tooi, N., Amagai, Y., Nakatsuji, N., & Aiba, K. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006722 · Cited by 107
“Among them, SMA patient’s hiPSCs showed a cell-death phenotype [52].”
BackgroundChun, Y. S., Chaudhari, P., & Jang, Y.-Y. (2010) · International Journal of Biological Sciences · doi:10.7150/ijbs.6.796 · Cited by 118
“reported the differentiation of iPSC-derived motor neurons from a patient diagnosed with a genetic from of spinal muscular atrophy (SMA), a neurodegenerative disease that leads to loss of lower motor neurons (11).”
BackgroundDrouin‐Ouellet, J., Lau, S., Brattås, P. L., Rylander Ottosson, D., Pircs, K., Grassi, D. A., Collins, L. M., Vuono, R., Andersson Sjöland, A., Westergren‐Thorsson, G., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607471 · Cited by 110
“Although this approach has led to important insights into neurodevelopmental disorders and mechanisms underlying neural pathologies (Ebert et al , 2009; Lee et al , 2009; Lafaille et al , 2012), a number of studies show that reprogramming into pluripotency resets the age of the cells such that the…”
Neely, M. D., Litt, M. J., Tidball, A. M., Li, G. G., Aboud, A. A., Hopkins, C. R., Chamberlin, R., Hong, C. C., Ess, K. C., & Bowman, A. B. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300029t · Cited by 117
Amniotic Fluid Cells Are More Efficiently Reprogrammed to Pluripotency Than Adult Cells
Galende, E., Karakikes, I., Edelmann, L., Desnick, R. J., Kerenyi, T., Khoueiry, G., Lafferty, J., McGinn, J. T., Brodman, M., Fuster, V., et al. (2010) · Cellular Reprogramming · doi:10.1089/cell.2009.0077 · Cited by 104
“Such reprogrammed adult fibroblasts from individual patients have a potential for drug screening (Ebert et al., 2009; Egli et al., 2008) and regenerative therapies.”
Feeder- and serum-free establishment and expansion of human induced pluripotent stem cells
Totonchi, M., Taei, A., Seifinejad, A., Tabebordbar, M., Rassouli, H., Farrokhi, A., Gourabi, H., Aghdami, N., Salekdeh, G. H., & Baharvand, H. (2009) · The International Journal of Developmental Biology · doi:10.1387/ijdb.092903mt · Cited by 114
“Subsequent reports optimized this technique, and direct reprogramming was achieved in human cells (Aasen et al., 2008; Dimos et al., 2008; Ebert et al., 2009; Li et al., 2009; Lowry et al., 2008; Maherali et al., 2008; Nakagawa et al., 2008; Park et al., 2008a; Park et al., 2008b; Takahashi et al.,…”
BackgroundMethodYoshida, M., Kitaoka, S., Egawa, N., Yamane, M., Ikeda, R., Tsukita, K., Amano, N., Watanabe, A., Morimoto, M., Takahashi, J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.010 · Cited by 102
“We did not observe any progressive motor neuronal loss during culture, even during the longer time period, which Stem is contrary to the previous reports (Chang et al., 2011; Corti et al., 2012; Ebert et al., 2009; Sareen et al., 2012).”
BackgroundResultFrom genes to function: the next challenge to understanding multiple sclerosis
Fugger, L. H., Friese, M. A., & Bell, J. I. (2009) · Nature reviews. Immunology · doi:10.1038/nri2554 · Cited by 129
Mollamohammadi, S., Taei, A., Pakzad, M., Totonchi, M., Seifinejad, A., Masoudi, N., & Baharvand, H. (2009) · Human Reproduction · doi:10.1093/humrep/dep244 · Cited by 112
“…et al., 2007; Yu et al., 2007; Aasen et al., 2008; Dimos et al., 2008; Huangfu et al., 2008; Lowry et al., 2008; Maherali et al., 2008; Nakagawa et al., 2008; Park et al., 2008a, b; Ebert et al., 2009; Li et al., 2009), providing an invaluable contribution to the field of regenerative medicine.”
BackgroundWang, Y., Zheng, C., Jiang, Y., Zhang, J., Chen, J., Yao, C., Zhao, Q., Liu, S., Chen, K., Du, J., et al. (2012) · Cell Research · doi:10.1038/cr.2012.23 · Cited by 114
Soga, M., Ishitsuka, Y., Hamasaki, M., Yoneda, K., Furuya, H., Matsuo, M., Ihn, H., Fusaki, N., Nakamura, K., Nakagata, N., et al. (2015) · Stem Cells · doi:10.1002/stem.1917 · Cited by 100
Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells under Xeno-free Conditions
Rodríguez-Pizà, I., Richaud-Patin, Y., Vassena, R., González, F., Barrero, M. J., Veiga, A., Raya, A., & Belmonte, J. C. I. (2010) · Stem Cells · doi:10.1002/stem.248 · Cited by 103
Newman, A. M., & Cooper, J. B. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-117 · Cited by 108
“GSE11508 was downloaded from the Gene Expression Omnibus (GEO, [25] as a quantile-normalized file, while the additional GEO datasets [46-50] (listed in Additional file 3, Table S5) were downloaded as raw CEL files and normalized together with Robust Multi-Chip Averaging (RMA) using the Affymetrix Expression Console so…”
MethodNeurodevelopmental disorders involving genomic imprinting at human chromosome 15q11–q13
Chamberlain, S. J., & Lalande, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.011 · Cited by 102
Primary cells and stem cells in drug discovery: emerging tools for high-throughput screening
Eglen, R., & Reisine, T. (2011) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2010.0305 · Cited by 100
“56– 59 Optimal disease modeling is a major advantage for using hiPS cells over primary cells when one considers that hiPS cells can be cultured in almost unlimited amounts—making them ideal for HTS assay protocols ( Tables 1 and 2 ).”
Human pluripotent stem cells in drug discovery and predictive toxicology
Laustriat, D., Gide, J., & Peschanski, M. (2010) · Biochemical Society Transactions · doi:10.1042/bst0381051 · Cited by 101
Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling
Koch, P., Kokaia, Z., Lindvall, O., & Brüstle, O. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70202-9 · Cited by 110
Current status of drug screening and disease modelling in human pluripotent stem cells
Rajamohan, D., Matsa, E., Kalra, S., Crutchley, J., Patel, A., George, V., & Denning, C. (2013) · BioEssays · doi:10.1002/bies.201200053 · Cited by 99
“Outside the cardiovascular system, the survival motor neuron 2 gene (SMN2) gene is implicated in development of spinal muscular atrophy in humans, but this gene is not present in mice, flies and worms [21].”
BackgroundDiversity among POU transcription factors in chromatin recognition and cell fate reprogramming
Malik, V., Zimmer, D., & Jauch, R. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2748-5 · Cited by 98
Induced pluripotent stem cells and reprogramming: seeing the science through the hype
Belmonte, J. C. I., Ellis, J., Hochedlinger, K., & Yamanaka, S. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2700 · Cited by 108
“For spinal muscular atrophy (SMA), the neuronal pathology was modelled and reversed with valproic acid, establishing the principle that drug screens could be performed using patient iPS cell”
BackgroundCRISPR-mediated genome editing and human diseases
Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.07.003 · Cited by 83
Thatava, T., Kudva, Y. C., Edukulla, R., Squillace, K., De Lamo, J. G., Khan, Y. K., Sakuma, T., Ohmine, S., Terzic, A., & Ikeda, Y. (2013) · Molecular Therapy · doi:10.1038/mt.2012.245 · Cited by 96
Differential neuronal vulnerability identifies IGF-2 as a protective factor in ALS
Allodi, I., Comley, L., Nichterwitz, S., Nizzardo, M., Simone, C., Benitez, J. A., Cao, M., Corti, S., & Hedlund, E. (2016) · Scientific Reports · doi:10.1038/srep25960 · Cited by 96
iPS cell technology in regenerative medicine
Lengner, C. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05213.x · Cited by 95
Song, B., Sun, G., Herszfeld, D., Sylvain, A., Campanale, N. V., Hirst, C. E., Caine, S., Parkington, H. C., Tonta, M. A., Coleman, H. A., et al. (2012) · Stem Cell Research · doi:10.1016/j.scr.2011.12.001 · Cited by 94
“, 2008), attracting considerable worldwide attention in disease modeling, drug screening and regenerative medicine (Ebert et al., 2009).”
BackgroundInfluentialPsychiatric Brain Banking: Three Perspectives on Current Trends and Future Directions
Deep-Soboslay, A., Benes, F. M., Haroutunian, V., Ellis, J. K., Kleinman, J. E., & Hyde, T. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.025 · Cited by 92
Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C.-W., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp333 · Cited by 94
“To this end, a mixed population of SMA neurons ( 25–35% of total population) and astrocytes differentiated from induced pluripotent stem (iPS) cells were treated with 150 mg/ml TC007 for 48 h (29).”
BackgroundMethodResultInfluentialSelf-citationTwo decades of embryonic stem cells: a historical overview
Eguizabal, C., Aran, B., Chuva de Sousa Lopes, S. M., Geens, M., Heindryckx, B., Panula, S., Popovic, M., Vassena, R., & Veiga, A. (2019) · Human Reproduction Open · doi:10.1093/hropen/hoy024 · Cited by 91
“Already in 2009, the derivation of patient-specific iPSCs from a child with spinal muscular atrophy showed disease-related deficits in the motor neurons generated in vitro (Ebert et al., 2009).”
BackgroundReliable generation of induced pluripotent stem cells from human lymphoblastoid cell lines
Barrett, R., Ornelas, L., Yeager, N., Mandefro, B., Sahabian, A., Lenaeus, L., Targan, S. R., Svendsen, C. N., & Sareen, D. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0121 · Cited by 83
Self-citationChang, T., Zheng, W., Tsark, W., Bates, S., Huang, H., Lin, R.-J., & Yee, J.-K. (2011) · Stem Cells · doi:10.1002/stem.749 · Cited by 92
Lemonnier, T., Blanchard, S., Toli, D., Roy, E., Bigou, S., Froissart, R., Rouvet, I., Vitry, S., Heard, J. M., & Bohl, D. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr285 · Cited by 116
“For neural differentiation, neurospheres were generated as previously described (31).”
MethodMacArthur, C. C., Fontes, A., Ravinder, N., Kuninger, D., Kaur, J., Bailey, M., Taliana, A., Vemuri, M. C., & Lieu, P. T. (2012) · Stem Cells International · doi:10.1155/2012/564612 · Cited by 91
“…by a Nonintegrating RNA Sendai Virus Vector in Feeder-Free or Xeno-Free Conditions Chad C. MacArthur,1 Andrew Fontes,1 Namritha Ravinder,2 David Kuninger,1 Jasmeet Kaur,1 Matthew Bailey,1 Antje Taliana,2 Mohan C. Vemuri,3 and Pauline T. Lieu1 1 Primary and Stem Cell Systems, Life Technologies…”
BackgroundInfluentialFreund, C. M. A. H., & Mummery, C. L. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22164 · Cited by 108
“Recently it has been shown that a human iPS cell model of spinal muscular atrophy (SMA) can recapitulate at least some aspects of this genetic disorder [Ebert et al., 2009].”
BackgroundFujikura, J., Nakao, K., Sone, M., Noguchi, M., Mori, E., Naito, M., Taura, D., Harada‐Shiba, M., Kishimoto, I., Watanabe, A., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2508-2 · Cited by 92
“More recently, disease-specific iPS cells have been generated from fibroblasts obtained from patients with various diseases [7–14], although not with mitochondrial diseases.”
BackgroundNew lessons learned from disease modeling with induced pluripotent stem cells
Önder, T. T., & Daley, G. Q. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.05.005 · Cited by 97
Functional Neuromuscular Junctions Formed by Embryonic Stem Cell-Derived Motor Neurons
Umbach, J. A., Adams, K. L., Gundersen, C. B., & Novitch, B. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036049 · Cited by 107
“Recent studies have further shown that MNs can be similarly produced from induced pluripotent stem cells (IPSC) including those derived from ALS and SMA patients [10–12], and through transcription factor-mediated reprogramming of fibroblasts [13].”
BackgroundFilling the Gap: Neural Stem Cells as A Promising Therapy for Spinal Cord Injury
Pereira, I. M., Marote, A., Salgado, A. J., & Silva, N. A. (2019) · Pharmaceuticals · doi:10.3390/ph12020065 · Cited by 98
“The establishment of some disease-specific iPSCs lines have already allowed a better understanding of the mechanisms that trigger and are behind certain diseases [108].”
BackgroundWilson, A. A., Ying, L., Liesa, M., Segeritz, C., Mills, J. A., Shen, S. S., Jean, J., Lonza, G. C., Liberti, D. C., Lang, A., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.021 · Cited by 99
“Recently, the discovery of induced pluripotent stem cells (iPSCs) (Takahashi and Yamanaka, 2006) has made it possible tomodel a variety of genetic diseases in vitro using patient-derived stem cells (Ebert et al., 2009; Park et al., 2008; Rashid et al., 2010).”
BackgroundOhmine, S., Squillace, K. A., Hartjes, K. A., Deeds, M. C., Armstrong, A. S., Thatava, T., Sakuma, T., Terzic, A., Kudva, Y. C., & Ikeda, Y. (2012) · Aging · doi:10.18632/aging.100428 · Cited by 90
“It is notable that iPS cells from patients with spinal muscular atrophy, familial dysautonomia and LEOPARD syndrome recapitulated the respective disease phenotypes upon redifferentiation [35-37], underscoring the value of derivation of patient-specific iPS cells for disease modeling and molecular diagnostics.”
BackgroundBrennan, S. K., Wang, Q., Tressler, R., Harley, C. B., Go, N. F., Bassett, E., Huff, C. A., Jones, R. J., & Matsui, W. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012487 · Cited by 92
“Within embryonic stem cells, specific transcriptional regulators, such as OCT3/4, NANOG, and SOX2 are critical for regulating selfrenewal and pluripotency [37–39].”
BackgroundTherapeutic Translation of iPSCs for Treating Neurological Disease
Yu, D. X., Marchetto, M. C., & Gage, F. H. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.018 · Cited by 94
Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery
Braam, S. R., Passier, R., & Mummery, C. L. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.001 · Cited by 86
Kudva, Y. C., Ohmine, S., Greder, L. V., Dutton, J. R., Armstrong, A. S., Lamo, J. G. D., Khan, Y. K., Thatava, T., Hasegawa, M., Fusaki, N., et al. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2011-0044 · Cited by 89
Medvedev, S. P., Grigor’eva, E. V., Shevchenko, A. I., Malakhova, A. A., Dementyeva, E. V., Shilov, A. A., Pokushalov, E. A., Zaidman, A. M., Aleksandrova, M. A., Plotnikov, E. Y., et al. (2010) · Stem Cells and Development · doi:10.1089/scd.2010.0249 · Cited by 95
Induced pluripotent stem cells and personalized medicine: current progress and future perspectives
Chun, Y. S., Byun, K., & Lee, B. (2011) · Anatomy & Cell Biology · doi:10.5115/acb.2011.44.4.245 · Cited by 106
“hiPSCs have been generated from patients with various diseases [6-10], with several groups reporting disease-specific phenotypes when these cells subsequently differentiate to directed functional cells [9, 11-19].”
BackgroundSpinal muscular atrophy: Development and implementation of potential treatments
Arnold, W. D., & Burghes, A. H. M. (2013) · Annals of Neurology · doi:10.1002/ana.23995 · Cited by 96
“Induced pluripotent stem cells have been developed from SMA patients, and neurons/motor neurons do show a mild phenotype.(50) These cells are being used in screens to identify drug compounds.”
BackgroundDifferentiation of Human Limbal-Derived Induced Pluripotent Stem Cells Into Limbal-Like Epithelium
Sareen, D., Saghizadeh, M., Ornelas, L., Winkler, M. A., Narwani, K., Sahabian, A., Funari, V. A., Tang, J., Spurka, L., Punj, V., et al. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0076 · Cited by 91
Self-citationConcise Review: Induced Pluripotent Stem Cell Research in the Era of Precision Medicine
Hamazaki, T., Rouby, N. M. E., Fredette, N. C., Santostefano, K. E., & Terada, N. (2017) · Stem Cells · doi:10.1002/stem.2570 · Cited by 95
A feedback loop regulates splicing of the spinal muscular atrophy-modifying gene, SMN2
Jodelka, F. M., Ebert, A. D., Duelli, D. M., & Hastings, M. L. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq425 · Cited by 98
“(D) Immunoblot analysis of SMN, hnRNP Q/R, Tra2b1 (SFRS10) and b-actin (loading control) in cell lysates from human-induced pluripotent stem (iPS) cells derived from an SMA patient or an unaffected family member (wt) (42).”
BackgroundMethodSelf-citationTiscórnia, G., Lorenzo-Vivas, E., Matalonga, L., Berniakovich, I., Barragán, M., Eguizábal, C., Gort, L., Gonzãlez, F., Mellet, C. O., Fernández, J. M. G., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds471 · Cited by 93
Schwab, A. J., & Ebert, A. D. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.11.004 · Cited by 83
“…were used (GM003814 Coriell Institute, GM02183 Coriell Insti- 1048 Stem Cell Reports j Vol. 5 j 1039–1052 j December 8, 2015 j ª2015 Th tute, and iPSK3; Ebert et al., 2009; Si-Tayeb et al., 2010; HD iPSC Consortium, 2012). iPSCs were grown in feeder-free conditions on Matrigel substrate in…”
MethodSelf-citationGrabundžija, I., Wang, J., Sebe, A., Erdei, Z., Kajdi, R., Devaraj, A., Steinemann, D., Szuhai, K., Stein, U., Cantz, T., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1305 · Cited by 102
“As previously seen with viral vector-derived human iPS cell lines, which sustain a low but detectable residual transgene expression (55,56), the SB-derived human iPS cells showed low expression of the reprogramming transgenes.”
BackgroundTissue-Engineered Skeletal Muscle Models to Study Muscle Function, Plasticity, and Disease
Khodabukus, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.619710 · Cited by 99
The Promise of Stem Cell Research in Pigs and Other Ungulate Species
Telugu, B. P. V. L., Ezashi, T., & Roberts, R. M. (2009) · Stem Cell Reviews and Reports · doi:10.1007/s12015-009-9101-1 · Cited by 88
Induced pluripotent stem cells for modelling human diseases
Unternaehrer, J. J., & Daley, G. Q. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0017 · Cited by 80
Haston, K. M., & Finkbeiner, S. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103548 · Cited by 82
“, Spinal muscular atrophy (SMA)] (66), these have been harder to detect in iPSC-derived cells from late-onset diseases unless they were captured by a highly sensitive detection platform (59, 64, 75, 76).”
BackgroundTang, Z.-H., Chen, J.-R., Zheng, J., Shi, H., Ding, J., Qian, X., Zhang, C., Chen, J., Wang, C.-C., Li, L., et al. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0252 · Cited by 87
Decreased sirtuin deacetylase activity in LRRK2 G2019S iPSC-derived dopaminergic neurons
Schwab, A. J., Sison, S. L., Meade, M. R., Broniowska, K. A., Corbett, J. A., & Ebert, A. D. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.010 · Cited by 80
“Three previously characterized unaffected control lines were used (GM003814 Coriell Institute, GM02183 Coriell Institute, iPSK3; Ebert et al., 2009; Si-Tayeb et al., 2010; HD iPSC Consortium, 2012).”
MethodSelf-citationMallon, B. S., Hamilton, R. S., Kozhich, O. A., Johnson, K. R., Fann, Y. C., Rao, M. S., & Robey, P. G. (2014) · Stem Cell Research · doi:10.1016/j.scr.2013.11.010 · Cited by 79
“Human induced pluripotent stem cells (hiPSCs) share key features and potential of human embryonic stem cells (hESCs) and allow the generation of patient-specific material (Ebert et al., 2009; Soldner et al., 2009).”
BackgroundLee, S., Cuvillier, J., Lee, B., Shen, R., Lee, J. W., & Lee, S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114515109 · Cited by 88
Mohamad, O., Drury-Stewart, D., Song, M., Ben, F., Chen, D., Yu, S. P., & Wei, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064160 · Cited by 88
“lished to differentiate iPS cells to neurons and use them to treat or model neurodegenerative diseases [14–21].”
BackgroundVariability in the generation of induced pluripotent stem cells: Importance for disease modeling
Vitale, A. M., Matigian, N. A., Ravishankar, S., Bellette, B., Wood, S. A., Wolvetang, E. J., & Mackay-Sim, A. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0043 · Cited by 79
Concise Review: Drug Discovery in the Age of the Induced Pluripotent Stem Cell
Ko, H. C., & Gelb, B. D. (2014) · Stem Cells Translational Medicine · doi:10.5966/sctm.2013-0162 · Cited by 80
The challenge of immunogenicity in the quest for induced pluripotency
Fairchild, P. J. (2010) · Nature reviews. Immunology · doi:10.1038/nri2878 · Cited by 92
“When this approach has been used to model early-onset diseases, functional assays have shown that there are specific defects in the disease-associated cell types that are absent from equivalent cells differentiated from control iPSC lines: for example, iPSCs derived from a child with spinal muscular atrophy gave rise…”
BackgroundFunctional Maturation of Human Stem Cell-Derived Neurons in Long-Term Cultures
Lam, R. S., Töpfer, F. M., Wood, P. G., Busskamp, V., & Bamberg, E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169506 · Cited by 87
Pharmacogenetics of Lithium Response in Bipolar Disorder
McCarthy, M. J., Leckband, S. G., & Kelsoe, J. R. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.127 · Cited by 79
Maioli, M., Rinaldi, S., Santaniello, S., Castagna, A., Pigliaru, G., Gualini, S., Cavallini, C., Fontani, V., & Ventura, C. (2013) · Cell Transplantation · doi:10.3727/096368912x657297 · Cited by 79
“In this regard, cellular reprogramming of somatic cells into induced pluripotent stem (iPS) cells and subsequent differentiation to mature cells have opened up new possibilities for tissue regeneration and repair (4,24,25,32).”
BackgroundSelvaraj, V., Plane, J. M., Williams, A. J., & Deng, W. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.01.002 · Cited by 88
Groen, E. J. N., Perenthaler, E., Courtney, N. L., Jordan, C. Y., Shorrock, H. K., van der Hoorn, D., Huang, Y.-T., Murray, L. M., Viero, G., & Gillingwater, T. H. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy195 · Cited by 86
Heman-Ackah, S. M., Bassett, A. R., & Wood, M. J. A. (2016) · Scientific Reports · doi:10.1038/srep28420 · Cited by 79
Cha, M.-Y., Kwon, Y.-W., Ahn, H.-S., Jeong, H., Lee, Y. Y., Moon, M., Baik, S. H., Kim, D. K., Song, H., Yi, E. C., et al. (2017) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0081 · Cited by 76
“Seq-ing” Insights into the Epigenetics of Neuronal Gene Regulation
Telese, F., Gamliel, A., Skowronska‐Krawczyk, D., García-Bassets, I., & Rosenfeld, M. G. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.034 · Cited by 88
“, 2007), and then differentiated into neurons (Brennand et al., 2011; Chamberlain et al., 2010; Ebert et al., 2009; Israel et al., 2012; Karumbayaram et al., 2009; Marchetto et al., 2010; Park et al., 2008; Pas xca et al., 2011).”
A Transcriptional Roadmap to the Induction of Pluripotency in Somatic Cells
Wang, Y., Mah, N., Prigione, A., Wolfrum, K., Andrade-Navarro, M. A., & Adjaye, J. (2010) · Stem Cell Reviews and Reports · doi:10.1007/s12015-010-9137-2 · Cited by 84
“the derivation of human iPS cells, but also further studied the reprogramming mechanisms, differentiation potentials, and applications of these human iPS cells [9–17].”
BackgroundReprogramming with defined factors: from induced pluripotency to induced transdifferentiation
Masip, M., Veiga, A., Belmonte, J. C. I., & Simón, C. (2010) · Molecular Human Reproduction · doi:10.1093/molehr/gaq059 · Cited by 85
Efficient induction of functional neurons from adult human fibroblasts
Pfisterer, U., Wood, J., Nihlberg, K., Hallgren, O., Bjermer, L., Westergren-Thorsson, G., Lindvall, O., & Parmar, M. (2011) · Cell Cycle · doi:10.4161/cc.10.19.17584 · Cited by 77
“Such cellular models will serve as valuable tools for understanding disease pathogenesis and progression.(3-5) The extent of genetic and epigenetic reprogramming and the mechanism for induction of pluripotency remains to be elucidated.”
BackgroundModeling Parkinson’s Disease Using Induced Pluripotent Stem Cells
Byers, B., Lee, H. D., & Pera, R. A. R. (2012) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-012-0270-y · Cited by 84
Creating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders
Brennand, K. J., Marchetto, M. C., Benvenisty, N., Brüstle, O., Ebert, A., Izpisua Belmonte, J. C., Kaykas, A., Lancaster, M. A., Livesey, F. J., McConnell, M. J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.011 · Cited by 77
“Ebert closed by discussing recent findings from hiPSC astrocyte studies regarding the cell non-autonomous effects underlying reduced synaptic puncti in spinal muscular atrophy (SMA) hiPSC-derived motor neurons (Ebert et al., 2009; Sareen et al., 2012).”
Self-citationTakahashi, H., & Okano, T. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500194 · Cited by 82
Comparing ESC and iPSC—Based Models for Human Genetic Disorders
Halevy, T., & Urbach, A. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3041146 · Cited by 88
“atrophy Wang 2013 [27] Knockdown of SMN Ebert 2009 [28] Lentiviruses ESCs ~ iPSCs”
BackgroundResultNissan, X., Larribere, L., Saidani, M., Hurbain, I., Delevoye, C., Feteira, J., Lemaitre, G., Peschanski, M., & Baldeschi, C. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019070108 · Cited by 74
“, Parkinson disease (40), spinal muscular atrophy (41), amyotrophic lateral sclerosis (42)].”
BackgroundReport from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
Bartlett, S. T., Markmann, J. F., Johnson, P., Korsgren, O., Hering, B. J., Scharp, D., Kay, T. W. H., Bromberg, J., Odorico, J. S., Weir, G. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001055 · Cited by 75
“Safety concerns regarding oncogene expression, viral immunogenicity, and genetic instability of hiPSCs may be averted with further improvements for derivation and expansion, making this a feasible cell source for future therapeutic purposes.(327) Human PSC lines that possess characteristics that thwart or downregulate…”
BackgroundRossoll, W., & Bassell, G. J. (2009) · Results and Problems in Cell Differentiation · doi:10.1007/400_2009_4 · Cited by 73
Directed Differentiation of Human Induced Pluripotent Stem Cells into Fallopian Tube Epithelium
Yucer, N., Holzapfel, M., Vogel, T. J., Lenaeus, L., Ornelas, L., Laury, A. R., Sareen, D., Barrett, R. J., Karlan, B. Y., & Svendsen, C. N. (2017) · Scientific Reports · doi:10.1038/s41598-017-05519-2 · Cited by 75
Self-citationMohtaram, N. K., Ko, J., King, C., Sun, L., Muller, N. J., Jun, M. B., & Willerth, S. M. (2014) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35392 · Cited by 77
Kramer, A. S., Harvey, A. R., Plant, G. W., & Hodgetts, S. I. (2013) · Cell Transplantation · doi:10.3727/096368912x655208 · Cited by 79
Regulation of Embryonic Stem Cell Pluripotency by Heat Shock Protein 90
Bradley, E., Bieberich, E., Mivechi, N. F., Tangpisuthipongsa, D., & Wang, G. (2012) · Stem Cells · doi:10.1002/stem.1143 · Cited by 79
Feyeux, M., Bourgois-Rocha, F., Redfern, A. J., Giles, P. J., Lefort, N., Aubert, S., Bonnefond, C., Bugi, A., Ruiz, M., Déglon, N., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds216 · Cited by 87
Kinnear, C., Chang, W. Y., Khattak, S., Hinek, A., Thompson, T., Rodrigues, D. C., Kennedy, K., Mahmut, N., Pasceri, P., Stanford, W. L., et al. (2012) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0054 · Cited by 79
Stem Cell Technology for the Study and Treatment of Motor Neuron Diseases
Lunn, J. S., Sakowski, S. A., Federici, T., Glass, J. D., Boulis, N. M., & Feldman, E. L. (2011) · Regenerative Medicine · doi:10.2217/rme.11.6 · Cited by 77
Survival Motor Neuron (SMN) protein is required for normal mouse liver development
Szunyogová, E., Zhou, H., Maxwell, G. K., Powis, R. A., Muntoni, F., Gillingwater, T. H., & Parson, S. H. (2016) · Scientific Reports · doi:10.1038/srep34635 · Cited by 83
Olesen, M. A., Villavicencio-Tejo, F., & Quintanilla, R. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00308-y · Cited by 88
Understanding ALS: new therapeutic approaches
Musarò, A. (2013) · The FEBS Journal · doi:10.1111/febs.12087 · Cited by 70
Kim, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.08.006 · Cited by 83
Astrocyte-produced miR-146a as a mediator of motor neuron loss in spinal muscular atrophy
Sison, S. L., Patitucci, T. N., Seminary, E. R., Villalón, E., Lorson, C. L., & Ebert, A. D. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx230 · Cited by 78
“These results were in contrast to our early work with human iPSCderived motor neuron cultures in which we showed clear loss of the motor neuron population in vitro by 6 weeks in culture (34,45).”
InfluentialSelf-citationToward stem cell-based phenotypic screens for neurodegenerative diseases
Khurana, V., Tardiff, D. F., Chung, C. Y., & Lindquist, S. L. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.79 · Cited by 78
Metadata
- Authors
- Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N.
- Affiliations
- University of Wisconsin–Madison (US)
- University of Missouri (US)
- Corresponding author
- Ebert, Allison D.
- Svendsen, Clive N.
- Venue
- Nature
- Published
- 2008-12-21
- Volume
- 457
- Issue
- 7227
- Pages
- 277-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2659408
- OpenAlex
- W2145492799
- Cited by
- 1,441
- References
- 42
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 28 · 2023: 31 · 2022: 36 · 2021: 33 · 2020: 46 · 2019: 54 · 2018: 53 · 2017: 60 · 2016: 85 · 2015: 109 · 2014: 112 · 2013: 145 · 2012: 199
- FWCI
- 58.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institute on Aging (T32AG027566)
- National Institute of General Medical Sciences (T32GM008396)
- National Institute of Neurological Disorders and Stroke (R01 NS41584, P01NS057778, R01NS041584)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD054413)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, motor neurons, SMN1, SMN2, dermal fibroblasts, disease modeling, neural progenitor cells, drug screening, inherited neurological diseases, Huntington's disease
- MeSH terms
- Cell Differentiation, Cell Separation, Cells, Cultured, Child, Female, Fibroblasts, Gene Expression Regulation, Humans, Male, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Cell Lineage, Pluripotent Stem Cells, Survival of Motor Neuron 1 Protein, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.